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Chroni c lateral epicondylosis (CLE, Btennis elbow[) is a common, debilitating, and expensive 1 condition accounting for 4Y7 of every 1000 primary care office visits annually. Among industrial workers, the prevalence of CLE 2 reaches 30%, with duration of symptoms of 6 mos to 2 yrs, regardless of therapy. 3, 4 Although CLE is often self-limited, up to 20% of cases are refractory to conservative care. 5 CLE and other chronic tendinopathies are now understood to be noninflammatory conditions 6 characterized by collagen degeneration, fibroblast proliferation, mucoid degeneration, and neovascularization. 7Y9 Although the source of pain is not known, relative rest, physical therapy, nonsteroidal anti-inflammatory drugs, surgery, and other forms of treatment have been assessed, but none is uniformly effective, and none has been shown to address the underlying degenerative pathophysiology. 10 Corticosteroid injections, although effective in the shortterm, may result in worse outcomes than watchful waiting in the long-term. 11 Indeed, content experts have suggested that CLE is best viewed as a selflimited condition and that Bwait and see[ may be a reasonable approach. 12 Prolotherapy (PrT) is an injection-based technique for treatment of chronic musculoskeletal pain including tendinopathy. 13 Hypertonic dextrose and morrhuate sodium are common injectants 14 used in previous pilot-level randomized controlled trials (RCTs). 15, 16 Preliminary evidence, although promising, is limited by lack of validated primary outcome measures, short follow-up, or lack of comparison with a wait-and-see control group. Therefore, the study team conducted a three-arm RCT to test the hypothesis that adults with symptomatic CLE receiving PrT with either hypertonic dextrose (PrT-D) or combined dextrose and morrhuate sodium (PrT-DM) will have greater improvement in elbow-related quality-of-life and biomechanical and magnetic resonance imaging (MRI)Ybased or ultrasound (US)-based outcomes than those in a wait-and-see control group.
METHODS
The study protocol was approved by the University of Wisconsin Health Sciences Institutional Review Board.
Eligibility Criteria and Participant Recruitment
The participants were recruited from the community and University of Wisconsin Sports, Rehabilitation and Family Medicine clinics and were followed from June 2009 to September 2010. The inclusion criteria were as follows: 18Y65 yrs old, self-reported lateral elbow pain present for the past 3 mos or longer and rated as 4 or higher on a 0Y10 ordinal response scale (BWhat was the average level of your left/right elbow pain over the last week?[), presence of pain over the lateral epicondyle on palpation and with resisted wrist extension during physical examination (D. Rabago), 17, 18 and having failed at least one of the three most common treatments for CLE (nonsteroidal anti-inflammatory drugs, physicianinitiated physical therapy, or a corticosteroid injection). The exclusion criteria included the following: previous elbow PrT; other elbow injection-based therapies within the past 3 mos; other concurrent upper extremity pathologies; previous upper extremity surgery; self-reported pregnancy; significant comorbidity precluding participation; bleeding disorders; allergy or intolerance to the study medication; chronic use of opioid, anticoagulant, or immunosuppressive medication; and standard MRI-related exclusions at the authors' institution (http://www.uwhealth.org/ healthfacts/B_EXTRANET_HEALTH_INFORMATION-FlexMember-Show_Public_HFFY_11 16338 384 058.html). If both elbows were affected, each elbow was assessed separately for eligibility. Interested, eligible persons attended an informational meeting, consented, and were enrolled.
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Study Design
The participants were randomly assigned to the blinded PrT (PrT-D or PrT-DM) or wait-and-see groups using a 1:1 computer-generated randomization. All participants were followed for 16 wks after entry; to aid participant retention, the participants in the wait-and-see group were offered PrT at 16 wks and exited from this study. The participants receiving PrT were additionally evaluated at 32 wks after entry. The participants receiving PrT and the assessors of the biomechanical and MRI outcomes were blinded to the injection group status and timing of injections.
Interventions
The PrT injections were performed under US guidance by the injector (K. S. Lee) at the University of Wisconsin Center for Musculoskeletal Ultrasound at 1, 4, and 8 wks after entry, using either dextrose or dextroseYmorrhuate sodium solutions (Table 1) prepared by the injector at the time of the procedure. Tenderness at the lateral epicondyle was confirmed by palpation, and the participants underwent a US evaluation of the lateral elbow structures using a Philips HDI 5000 US with specialized 12.5-MHz 38-mm linear array scan heads and tissue-specific presets for imaging superficial tendons and ligaments. Skin wheals of analgesic 1% lidocaine were placed. Under continuous US evaluation, 0.5 ml of the prepared PrT solution was injected into the lateral epicondyle (22 gauge, 1.5-in long needle). Then, up to 2.5 ml of the solution was Bpeppered[ on the bone along a short segment of the tendon and the annular ligament at the areas of palpated tenderness and US-documented pathology. After the injection, the participants were offered 20 tablets of 325 mg of acetaminophen for Bas-needed[ analgesia and were telephoned on day 2 to inquire about side effects or adverse events. They were advised on relative rest for 2Y3 days after the procedure and progressive resumption of routine activity during 1 mo.
The participants in the wait-and-see group were counseled about CLE risk modification in daily living and work activities.
Adherence and Precautions
All participants were reminded at each contact to avoid nonsteroidal anti-inflammatory drugs and new therapies for CLE and to limit overuse of the elbow during the study period. They were encouraged to attend all treatment and assessment sessions. The participants in the wait-and-see group were contacted by telephone at the same intervals as the participants receiving PrT were seen during the 16 wks of study to minimize contact bias.
Outcome Measures
The primary outcome was the change in the composite score on the Patient-Rated Tennis Elbow Evaluation (PRTEE), a CLE-specific questionnaire evaluating disease-specific quality-of-life. 18, 19 The elbow pain (five items) and function (ten items) subscales of the PRTEE show excellent reliability (interclass correlation coefficients, pain, 0.96; function, 0.92; and composite, 0.96) and sensitivity to change. 18, 19 Scores range from 0 (good quality-oflife, no pain or disability) to 100 (poor quality-of-life, extreme pain or disability). The minimal clinical important difference was established for the PRTEE at 11 points or 37% improvement compared with baseline (Bmuch better[ or Bcompletely recovered[). 20 The PRTEE was collected in person at baseline; 4, 8, and 16 wks (all participants); and 32 wks after entry (only the participants receiving PrT). The participants receiving PrT provided the PRTEE data before their PrT procedures.
The secondary outcomes included pain-free grip strength, a commonly used objective measure of CLE-related disability, with good test-retest (Pearson correlation, r Q 0.8) and validity (T3%) measures. 21, 22 For the grip-strength evaluation, the participants sat in a chair with their shoulder flexed at 90 degrees, their elbow extended, and their forearm in a neutral position. All participants were instructed to squeeze the Baseline (Fabrication Enterprises Inc, White Plains, NY) dynamometer set at 2 in and cease squeezing before the onset of pain. The mean of three replications performed before any procedure and separated by 60-sec intervals was recorded at baseline and at 8 and 16 wks (all participants) and 32 wks (only participants receiving PrT) after entry.
The secondary outcomes also included the MRI and US elbow assessments. The study team used an ordinal 0Y3 CLE severity grading based on the T1 and T2 MRI signal intensity at the common extensor tendon that corresponds to areas of collagen disruption, mucoid degeneration, or neovascularization on histopathologic examination, 23, 24 Grade 1 consisted of tendon thickening and intermediate T1 and T2 signal intensity. 23, 24 Grade 2 corresponded to a partial-thickness tear. Grade 3 corresponded to a fullthickness tear. All participants were assessed using an Artoscan 0.2 Tesla MRI scanner at baseline and 16 wks; the participants receiving PrT were also assessed at 32 wks. The MRI examinations consisted of an axial T1-weighted spin-echo sequence (repetition time (TR) and echo time (TE), 620/10 ms), an axial T2-weighted www.ajpmr.com spin-echo sequence (TR/TE, 2200/80 ms), and a coronal T2-weighted spin-echo sequence (TR/TE, 2200/80 ms), all performed with a 15-cm field of view, a 192 Â 160 matrix, and a 3.5-mm slice thickness. All MRI examinations were reviewed by a fellowship-trained musculoskeletal radiologist (R. Kijowski). CLE severity at baseline and follow-up was further characterized by US of the common extensor tendon, using published ordinal scales for hypoechogenicity, tendon thickness, and neovascularity, which have been reported to be associated with tendinopathy as a biomarker and potential source of pain. 25 US assessment also included acoustoelastography, a novel measure with the potential to objectively measure tendon tissue stiffness as a biomarker for baseline disease and response to therapy. 26 The US-based methods and results will be reported in a subsequent article.
The tertiary outcomes included treatment satisfaction rating of the participant receiving PrT, using a 5-point (0, very dissatisfied; 5, very satisfied) scale. Demographics, duration of elbow pain, and information on previous therapy for CLE were collected at baseline to characterize the sample and to evaluate as covariates (age, sex, and baseline CLE severity). The participants were queried about any new therapies for CLE and were able to make brief qualitative comments at all follow-up time points.
Analysis
The a priori sample size calculation was guided by an RCT reporting a 68% absolute effect size of PrT for severe CLE compared with saline injections. 15 Assuming a similar effect size on the PRTEE measure in the PrT groups, minimal change in the wait-and-see control group, and minimal loss to follow-up, the sample size to detect this difference on the PRTEE between either the PrT groups and the wait-and-see group was 10 participants per arm (N = 30; 80% power, two-sided > = 0.05).
The data were analyzed with SPSS version 19.0 statistical software 27 by intention to treat. Descriptive statistics were used to describe baseline characteristics. The unit of analysis was the individual elbow. Quantitative data were assessed using a general linear model at each time point, holding the PRTEE composite or subscale scores as the dependent variable, with group and time as respective random factors. Age and symptom duration were evaluated as covariates in the model. Grip strength was analyzed using a similar general linear model approach. Least significant difference post hoc analyses were carried out on the corresponding adjusted estimates for between-group comparisons. Paired t tests were used to estimate within-group differences. Statistical significance was assessed using two-tailed tests (P G 0.05). Missing values were addressed using a Blast-value-carried-forward[ strategy. 28 Ordinal MRI data are presented on a group-by-time basis.
RESULTS
Of the 134 persons screened by telephone, 44 met the eligibility criteria, and 31 persons were Under continuous US evaluation, 0.5 ml of PrT solution was injected into the lateral epicondyle; then, up to an additional 2 ml of the solution was peppered on the bone along a short segment of the tendon and the annular ligament at the areas of palpated tenderness and US-documented pathology. Dextrose and morrhuate PrT 1 ml of 5% morrhuate sodium + 1.5 ml of 50% dextrose + 2 ml of 1% lidocaine + 2.5 ml of 0.9% saline (10-ml syringe)
Injection technique identical to the one above.
Postinjection procedures
The subjects were instructed to rest after the PrT injections for 5 mins. The participants were given 100 tablets of 325 mg of acetaminophen for as-needed analgesia; were given written instructions for aftercare; and were then telephoned after 2 days to inquire about comments, questions, side effects, or adverse events. enrolled and randomized. Because four enrollees dropped out before the completion of baseline data collection, 27 participants with 32 affected elbows were included in the analysis (Fig. 1) . The participants receiving PrT-DM were slightly younger than those in other groups (P = 0.047); there were no other significant differences between the groups ( Table 2 ). The study sample was mostly men (65%), had a mean (SD) age of 48.2 (7.8) yrs, and reported more than 3 yrs of elbow pain. Baseline MRI was available for 29 of 32 possible elbows; all MRI-imaged elbows showed detectable pathology, and 22 of 29 had features of moderate to severe disease. All 16 participants receiving PrT (20 total elbows) received three planned PrT sessions.
The participants receiving PrT-D reported a statistically significant improvement in composite (at 16 and 32 wks), pain (at 16 and 32 wks), and a All baseline differences between the groups were not significant except for age; the participants in the PrT-DM group were younger than those in the other two groups (P = 0.047).
www.ajpmr.com function (at 32 wks) PRTEE scores compared with baseline; the participants receiving PrT-DM reported a statistically significant improvement in composite (at 32 wks), pain (at 16 and 32 wks), and function (at 32 wks) PRTEE scores (Table 3 ). Composite PRTEE score improvement for both PrT-D and PrT-DM was in excess of minimal clinical important difference at 16 wks, whereas improvement in the wait-and-see PRTEE scores was not.
Age-and symptom durationYadjusted betweengroup comparisons showed that both PrT groups outperformed (P G 0.05) the wait-and-see group on several PRTEE measures. At 8 wks, the participants in both PrT groups had improved composite PRTEE scores compared with the wait-and-see group (P G 0.05). The PrT-DM group continued to outperform the wait-and-see group at week 16 on the PRTEE composite score (P G 0.05). The PRTEE subscale scores followed a similar pattern. The participants in both PrT groups had improved function subscale scores compared with the wait-and-see group at 8 and 16 wks (P G 0.05), and the participants receiving PrT-DM had improved pain subscale scores compared with the wait-and-see group at 16 wks (P G 0.05). The PrT-D group also showed greater grip strength than either the PrT-DM or the wait-and-see group at 8 and 16 wks (P G 0.05; Table 4 ). Grip strength did not change in the wait-and-see group by 16 wks and in the PrT-DM group by 16 or 32 wks.
CLE severity was evaluated using existing magnetic resonance images in all participants for whom baseline magnetic resonance images were available (n = 29). All participants had MRI-assessed disease at baseline; seven (23%) had grade 1, ten (33%) had grade 2, and twelve (40%) had grade 3 ( Table 5) . Over time, only minimal changes in MRI-assessed Between-group analysis at each time point used a general linear model, adjusted for age during the 16-wk portion of study: a Change in the PrT-D score and the PrT-DM score was greater than that of the wait-and-see group (P G 0.05); there were no significant differences between the PrT-D and the PrT-DM.
b Change in the PrT-D score was greater than that of the wait-and-see group (P G 0.05); there were no significant differences between the PrT-D and the PrT-DM and no significant difference between the PrT-DM and the wait and see.
CLE severity grade were noted for each participant. There were no within-or between-group differences in MRI severity scores.
Six (75%) of eight participants receiving PrT-D reported being Bsomewhat[ or Bvery[ satisfied; two (29%) participants reported Bneutral[ response (2/5) at 16 wks; there was no change in the satisfaction ratings at 32 wks. At 16 wks, seven (78%) of nine participants receiving PrT-DM reported being somewhat or very satisfied; one (11%), neutral; and one (11%), Bsomewhat dissatisfied[; at 32 wks, one participant was still somewhat dissatisfied but the remaining eight (89%) were somewhat or very satisfied. No participants reported starting new therapy for CLE. An inspection of the qualitative comments showed that all participants reported mild to moderate self-limited injection-related pain. This pain tended to resolve within 1 wk in the PrT-D group. However, the participants receiving PrT-DM reported more severe and persistent injectionrelated pain taking up to 3 wks to resolve. A 4-wk PrT session of one participant receiving PrT-DM was postponed by 2 wks because of postprocedural pain. There were no unexpected or serious adverse events.
DISCUSSION
This RCT of adults with symptomatic CLE found substantial, consistent, and significant improvements in composite or subscale PRTEE scores in response to two different PrT solutions compared with the wait-and-see control group at the 16-wk follow-up; improvement continued in the PrT groups to the 32-wk follow-up. This study is the first robust assessment of 20% dextrose PrT for CLE, the first comparison of two different PrT solutions, and the first to compare the two PrT solutions to natural history as represented by the wait-and-see control group. At 16 wks, improvement in the composite PRTEE score for both PrT groups substantially exceeded minimal clinical important difference on the PRTEE, whereas that of the wait-and-see control group participants did not; the PrT group participants' PRTEE scores continued improving through 32 wks. The participants receiving PrT-D seemed to improve more quickly and with less postinjection pain than did the PrT-DM group; at 32 wks, however, there was no difference between the PrT groups on any of the outcomes. Grip strength improved in the PrT-D group compared with both baseline and the two other groups.
These findings are consistent with those of multiple small RCTs, the methodologically strongest of which reported similar 16-wk improvements on a 0Y10 ordinal response pain scale and Grade  0  0  0  0  1  2  3  3  2  3  3  2  3  3  3  3  PrT-DM  Grade  0  0  0  0  1  3  3  3  2  3  3  3  3  4  2  2 There were no changes between or within groups. NA indicates not applicable. 15 and nonsignificant MRI changes. 29 Although the data cannot be directly compared, inspection suggests that the response to PrT in Scarpone et al. 15 was slightly more robust; the methodological and baseline participant differences may account for this. The current study used a slightly lower concentration of morrhuate sodium, performed injections under US guidance, and enrolled participants with less severe and more variable baseline CLE severity. These findings are also consistent with clinical experience; morrhuate sodium injections are understood to hurt more and are typically reserved for more severe cases refractory to less-irritating solutions such as dextrose alone. Direct comparison to previous studies and to studies involving steroid injections, laser, or more conventional therapies is also difficult given the methodological heterogeneity. Although corticosteroid injections have been regarded as standard of care for CLE, recent evidence suggests that these provide inferior long-term outcomes than do other treatments for CLE including wait and see. 30 Overall, these findings suggest that PrT may improve upon standard of care for CLE for some patients, especially because most participants were refractory to previous conventional therapies. Whether PrT can modify the disease at the tissue level is not known; the data from this study do not support such an effect discernable on MRI.
PrT is an evolving modality gaining popularity in sport, rehabilitation, and family medicine, although its mechanism of action is unclear and likely multifactorial. 14 The injectants likely have in< dependent biologic actions; two recent RCTs report outcomes favoring PrT compared with blinded saline injections. 15, 31 The proposed biologic mechanism of action has been reviewed. 14 32 ; animal model studies reported increased inflammatory markers 33 and a significantly enlarged cross-sectional area in medical collateral ligaments. 34 Morrhuate sodium is a sclerosing agent. Animal studies report a robust inflammatory response 33 and stronger medial collateral ligaments after injection with morrhuate sodium. 35, 36 The combined effect of the two agents has not been assessed in basic science studies, no previous studies have sought to optimize the concentration of either dextrose or morrhuate sodium, and no governing body has published guidelines for optimal concentrations of these injectants. The injectant concentration and protocol used in the current study are consistent with those used in the PrT community. The potential of PrT to stimulate the release of growth factors promoting soft tissue healing and a positive neural effect has also been suggested. Needle trauma and volume expansion of local tissue may also produce a tissue-level effect. 37 The combined effects of needle trauma, volume expansion, and dextrose and morrhuate-specific mechanisms may explain the positive findings for PrT in this study.
This study is limited by small sample size and high data variability; however, the response was robust enough to detect several between-group differences. This study does not include a blinded injection control group; therefore, some of the improvement reported by the participants in the active arms of this study may have resulted from being in an injection arm per se. However, a previous CLE PrT study reported improvement compared with blinded saline injections 15 ; comparison to natural history, as exemplified by a wait-and-see control arm, is an accepted clinical trial strategy, 11 and the challenge of selecting an appropriate control therapy in clinical trials assessing injection techniques has been noted. 37 The current study allows a direct comparison to natural history and facilitates the study of PrT as a modifier of underlying degenerative disease through assessment of MRI and US measures (manuscript in process). The injector and the assessor of the PRTEE data were not blinded to injection type, and the blinding of the participants who were injected and the biomechanical and MRI assessors was not formally assessed; the data are therefore subject to potential injector and assessor bias. The 16-wk follow-up portion of the RCT is relatively short; however, the primary outcome and grip strength data are consistent with a previous 16-wk study, the positive results of which were also noted at 16 wks and continued through 52 wks. 15 The strengths include RCT design; validated patientoriented outcomes; minimal missing data; and a large, consistent effect size in the PRTEE score change in both PrT groups compared with the waitand-see group.
Directions for Future Research
Determination of the clinical utility of PrT for CLE will require confirmation in a larger, longer effectiveness trial that includes biomechanical and imaging outcome measures to assess potential disease modification.
CONCLUSIONS
Among participants with CLE, PrT resulted in safe and significant improvements on validated CLE-specific quality-of-life, pain, and function measures and grip strength compared with the waitand-see control group at 16 wks and compared with baseline status through 32 wks. PrT may be an appropriate therapy for selected patients with refractory CLE.
